Arcus Biosciences Reports $128 Million Net Loss in Q1 2026, Revenue Declines 39%

Arcus Biosciences, Inc. reported a net loss of $128 million for the first quarter of 2026, compared to a net loss of $112 million in the same period of the previous year. The company's total revenues decreased by 39% to $17 million, down from $28 million in the first quarter of 2025. This decline was primarily attributed to a reduction in license and development services revenue from its collaboration with Gilead Sciences, which accounted for 88% of total revenues in the latest quarter. The company has not generated any revenue from product sales and anticipates continued significant losses as it advances its investigational products.

Operating expenses for the quarter increased slightly to $151 million from $150 million year-over-year, with research and development expenses remaining flat at $122 million. General and administrative expenses rose by 4% to $29 million, driven by increased stock-based compensation. The company reported a loss from operations of $134 million, reflecting a 10% increase compared to the prior year. Non-operating income also fell to $6 million from $10 million, primarily due to lower interest income and increased interest expenses related to its debt obligations.

In terms of strategic developments, Arcus announced that the option rights of Gilead under their collaboration agreement will expire on July 14, 2026, following Gilead's decision not to make a continuation payment. This decision will limit Gilead's access to additional programs in Arcus's early-stage pipeline. Additionally, the company has decided to discontinue the Phase 3 STAR-121 study of domvanalimab due to futility, which may impact its future development plans.

As of March 31, 2026, Arcus had cash, cash equivalents, and marketable securities totaling $876 million, which it believes will be sufficient to fund operations until at least the second half of 2028. The company is currently focused on advancing its late-stage clinical programs, particularly casdatifan, while winding down studies related to domvanalimab. Looking ahead, Arcus expects to streamline its operations and reduce costs, although it may need to raise additional capital to support its ongoing development efforts.

The company continues to face significant risks, including the need for regulatory approvals for its investigational products, potential delays in clinical trials, and competition from other biopharmaceutical companies. Arcus's ability to successfully navigate these challenges will be critical to its future growth and financial performance.